STADA og Alvotech hefja sölu á Uzpruvo, fyrstu líftæknilyfjahliðstæðunni við Stelara í Evrópu
22 juil. 2024 06h35 HE
|
Alvotech
Fréttatilkynning22. júlí 2024STADA og Alvotech hefja sölu á Uzpruvo, fyrstu líftæknilyfjahliðstæðunni við Stelara í Evrópu Líftæknilyfjahliðstæðan kemur á markað um leið og einkaleyfi fyrir...
STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across Europe
22 juil. 2024 06h35 HE
|
Alvotech
STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across Europe Launch of European-made Uzpruvo in Europe comes immediately upon expiry of exclusivity rights...
STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across Europe
22 juil. 2024 06h30 HE
|
Alvotech
STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across Europe
Alvotech Announces Closing of Private Debt Financing
11 juil. 2024 04h45 HE
|
Alvotech
REYKJAVIK, Iceland, July 11, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...
Alvotech lýkur við endurfjármögnun skulda með lægri fjármagnskostnaði og lengri lánstíma
11 juil. 2024 04h45 HE
|
Alvotech
Alvotech (NASDAQ: ALVO) tilkynnti í dag að endurfjármögnun skulda félagsins væri nú lokið. Með því hefur félagið lækkað fjármagnskostnað og lengt lánstíma útistandandi skulda. Að endurfjármögnuninni...
Alvotech Announces Closing of Private Debt Financing
11 juil. 2024 04h45 HE
|
Alvotech
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the closing of its previously...
Alvotech kynnir jákvæða niðurstöðu virknirannsóknar á AVT03, fyrirhugaðri líftæknilyfjahliðstæðu við Prolia og Xgeva
02 juil. 2024 09h00 HE
|
Alvotech
Jákvæðar niðurstöður rannsóknarinnar sýna sambærilega klíníska virkni AVT03 og samanburðarlyfsins Prolia (denosumab) í sjúklingum Endapunktur var einnig uppfylltur í tveimur klínískum rannsóknum þar...
Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
02 juil. 2024 09h00 HE
|
Alvotech
Positive topline results demonstrate clinical similarity between AVT03 and the reference biologic, Prolia® (denosumab) Two additional studies comparing the pharmacokinetics, safety, and tolerability...
Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
02 juil. 2024 09h00 HE
|
Alvotech
Positive topline results demonstrate clinical similarity between AVT03 and the reference biologic, Prolia® (denosumab) Two additional studies comparing the pharmacokinetics, safety, and tolerability...
Alvotech Issues New Shares to Holders of Convertible Bonds
01 juil. 2024 17h35 HE
|
Alvotech
REYKJAVIK, Iceland, July 01, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...